Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment

StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Oct 23, 2026 → Oct 23, 2027
See other at-risk trials from National Cancer Institute (NCI)

Record History

The 50 most recent of 126 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Oct 23, 2026 to Oct 23, 2027 Show 4 more changesShow less
    • Eligibility criteria expanded, about 27 words
    • Secondary endpoints: details revised at 2 of 4 entries
    • Site details revised at 3 of 27 sites
    • Publications: details revised at 1 of 1 entry
  2. Enrollment closed, study ongoing
    • Site details revised at 27 of 27 sites
    v125
  3. Study sites revised (27)v124
  4. Site details revised at 1 of 27 sitesv123
  5. Re-verified, no change to tracked fieldsv122
Show 45 earlier versionsHide 45 earlier versions
  1. Site details revised at 1 of 27 sitesv121
  2. 18 versions Re-verified since Mar 17, 2026, no change to tracked fieldsv103-v120
  3. Site details revised at 1 of 27 sitesv102
  4. Re-verified, no change to tracked fieldsv101
  5. Enrollment target: 35 to 30
    • Study description expanded, about 11 words
    v100
  6. 8 versions Re-verified since Feb 17, 2026, no change to tracked fieldsv92-v99
  7. Site details revised at 1 of 27 sitesv91
  8. 14 versions Re-verified since Jan 24, 2026, no change to tracked fieldsv77-v90
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial tests how well erdafitinib works in controlling IDH-wild type (WT), FGFR-TACC gene fusion positive gliomas that have come back after a period of improvement (recurrent) or that are growing, spreading, or getting worse (progressive). Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals tumor cells to multiply. This may help keep tumor cells from growing and may kill them. Giving erdafitinib may help to slow the growth of, or to shrink, tumor cells in patients with recurrent or progressive IDH-wild type gliomas with FGFR-TACC gene fusion.
Trial Details
NCT Number NCT05859334
Lead Sponsor National Cancer Institute (NCI)
Conditions
(from sponsor)		 Recurrent Glioma, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma
Related terms Glioma
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov